PriceTargets.com logo

Edwards Lifesciences - EW Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $75.67
  • Forecasted Upside: 8.81%
  • Number of Analysts: 26
  • Breakdown:
  • 0 Sell Ratings
  • 16 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
$69.54 As of 11/20/2024 01:00 AM ET
▼ -0.66 (-0.94%)

This chart shows the closing price for EW by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Edwards Lifesciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EW and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EW

Analyst Price Target is $75.67
▲ +8.81% Upside Potential
This price target is based on 26 analysts offering 12 month price targets for Edwards Lifesciences in the last 3 months. The average price target is $75.67, with a high forecast of $105.00 and a low forecast of $57.00. The average price target represents a 8.81% upside from the last price of $69.54.

This chart shows the closing price for EW for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 26 polled investment analysts is to hold stock in Edwards Lifesciences. This rating has held steady since August 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 9 hold ratings
  • 1 sell ratings
Ratings as of
5/31/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 9 hold ratings
  • 1 sell ratings
Ratings as of
8/29/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 9 hold ratings
  • 1 sell ratings
Ratings as of
11/27/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
2/25/2024
  • 0 strong buy ratings
  • 13 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
5/25/2024
  • 1 strong buy ratings
  • 11 buy ratings
  • 13 hold ratings
  • 0 sell ratings
Ratings as of
8/23/2024
  • 1 strong buy ratings
  • 10 buy ratings
  • 14 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 16 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 16 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/30/2024Daiwa AmericaDowngradeStrong-Buy ➝ Hold
10/28/2024Sanford C. BernsteinUpgradeStrong Sell ➝ Hold
10/25/2024Canaccord Genuity GroupLower TargetHold ➝ Hold$66.00 ➝ $63.00
10/25/2024JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$72.00 ➝ $78.00
10/25/2024Piper SandlerLower TargetNeutral ➝ Neutral$73.00 ➝ $70.00
10/25/2024Truist FinancialLower TargetHold ➝ Hold$71.00 ➝ $70.00
10/25/2024Robert W. BairdLower TargetNeutral ➝ Neutral$73.00 ➝ $68.00
10/11/2024Morgan StanleyReiterated RatingEqual Weight$70.00
10/8/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$85.00 ➝ $75.00
10/7/2024Canaccord Genuity GroupLower TargetHold ➝ Hold$77.00 ➝ $66.00
10/1/2024CitigroupLower TargetBuy ➝ Buy$83.00 ➝ $77.00
10/1/2024Evercore ISILower TargetIn-Line ➝ In-Line$76.00 ➝ $70.00
9/18/2024Jefferies Financial GroupDowngradeBuy ➝ Hold$85.00 ➝ $70.00
9/13/2024Truist FinancialLower TargetHold ➝ Hold$82.00 ➝ $71.00
9/12/2024OppenheimerReiterated RatingOutperform ➝ Outperform$90.00 ➝ $90.00
9/10/2024UBS GroupLower TargetNeutral ➝ Neutral$90.00 ➝ $75.00
9/9/2024BarclaysLower TargetOverweight ➝ Overweight$90.00 ➝ $80.00
9/9/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$90.00 ➝ $80.00
7/31/2024Daiwa AmericaUpgradeStrong-Buy
7/31/2024Daiwa Capital MarketsUpgradeNeutral ➝ Outperform
7/29/2024Wolfe ResearchUpgradeUnderperform ➝ Peer Perform
7/26/2024BarclaysLower TargetOverweight ➝ Overweight$101.00 ➝ $90.00
7/26/2024The Goldman Sachs GroupLower TargetBuy ➝ Buy$107.00 ➝ $91.00
7/25/2024Baird R WDowngradeStrong-Buy ➝ Hold
7/25/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$99.00 ➝ $90.00
7/25/2024TD CowenDowngradeBuy ➝ Hold$100.00 ➝ $70.00
7/25/2024Evercore ISILower TargetIn-Line ➝ In-Line$91.00 ➝ $76.00
7/25/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$101.00 ➝ $85.00
7/25/2024Deutsche Bank AktiengesellschaftLower TargetBuy ➝ Buy$103.00 ➝ $85.00
7/25/2024OppenheimerLower TargetOutperform ➝ Outperform$100.00 ➝ $90.00
7/25/2024Stifel NicolausLower TargetHold ➝ Hold$85.00 ➝ $70.00
7/25/2024Canaccord Genuity GroupLower TargetHold ➝ Hold$85.00 ➝ $77.00
7/25/2024Piper SandlerLower TargetNeutral ➝ Neutral$88.00 ➝ $73.00
7/25/2024Bank of AmericaDowngradeBuy ➝ Neutral$105.00 ➝ $75.00
7/25/2024Robert W. BairdDowngradeOutperform ➝ Neutral$102.00 ➝ $70.00
7/25/2024JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$105.00 ➝ $72.00
7/25/2024Truist FinancialDowngradeBuy ➝ Hold$110.00 ➝ $82.00
7/16/2024Truist FinancialBoost TargetBuy ➝ Buy$105.00 ➝ $110.00
7/10/2024CitigroupBoost TargetBuy ➝ Buy$105.00 ➝ $106.00
7/2/2024Evercore ISIBoost TargetIn-Line ➝ In-Line$89.00 ➝ $91.00
5/30/2024The Goldman Sachs GroupInitiated CoverageBuy$107.00
5/22/2024CitigroupUpgradeNeutral ➝ Buy$98.00 ➝ $105.00
5/14/2024Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$86.00 ➝ $103.00
5/7/2024BarclaysBoost TargetOverweight ➝ Overweight$100.00 ➝ $101.00
4/26/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$94.00 ➝ $99.00
4/26/2024Evercore ISILower TargetIn-Line ➝ In-Line$92.00 ➝ $89.00
4/26/2024Stifel NicolausBoost TargetHold ➝ Hold$83.00 ➝ $85.00
4/26/2024Piper SandlerBoost TargetNeutral ➝ Neutral$85.00 ➝ $88.00
4/15/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$95.00 ➝ $101.00
4/11/2024MizuhoBoost TargetBuy ➝ Buy$95.00 ➝ $105.00
4/4/2024Evercore ISIBoost TargetIn-Line ➝ In-Line$86.00 ➝ $92.00
4/3/2024CitigroupBoost TargetNeutral ➝ Neutral$90.00 ➝ $98.00
3/26/2024OTR GlobalUpgradeMixed ➝ Positive
3/21/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$95.00 ➝ $103.00
3/18/2024OppenheimerBoost TargetOutperform ➝ Outperform$93.00 ➝ $100.00
3/7/2024Bank of AmericaUpgradeNeutral ➝ Buy
2/7/2024Stifel NicolausBoost TargetHold ➝ Hold$70.00 ➝ $83.00
2/7/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$80.00 ➝ $95.00
2/7/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$82.00 ➝ $95.00
2/7/2024MizuhoBoost TargetBuy ➝ Buy$85.00 ➝ $95.00
2/2/2024Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$94.00
1/12/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$80.00 ➝ $82.00
1/4/2024Evercore ISIDowngradeOutperform ➝ In-Line$80.00 ➝ $77.00
12/22/2023Truist FinancialBoost TargetBuy ➝ Buy$78.00 ➝ $84.00
12/11/2023Truist FinancialBoost TargetBuy ➝ Buy$76.00 ➝ $78.00
12/11/2023CitigroupDowngradeBuy ➝ Neutral
12/4/2023Morgan StanleyLower TargetOverweight ➝ Overweight$102.00 ➝ $80.00
11/28/2023Wolfe ResearchDowngradePeer Perform ➝ Underperform$57.00
10/26/2023Stifel NicolausLower TargetHold ➝ Hold$87.00 ➝ $70.00
10/26/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$86.00 ➝ $82.00
10/26/2023Truist FinancialLower TargetBuy ➝ Buy$83.00 ➝ $76.00
10/26/2023MizuhoLower TargetBuy ➝ Buy$90.00 ➝ $85.00
10/26/2023Piper SandlerLower TargetNeutral ➝ Neutral$83.00 ➝ $68.00
10/26/2023CitigroupLower TargetBuy ➝ Buy$94.00 ➝ $85.00
10/26/2023Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$88.00 ➝ $75.00
10/16/2023Leerink PartnrsReiterated RatingMarket Perform
10/16/2023Leerink PartnersInitiated CoverageMarket Perform$75.00
10/2/2023CitigroupLower TargetBuy ➝ Buy$110.00 ➝ $94.00
9/26/2023OppenheimerUpgradeMarket Perform ➝ Outperform$90.00
9/8/2023Piper SandlerLower TargetNeutral ➝ Neutral$88.00 ➝ $83.00
8/17/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$96.00
8/1/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$96.00
7/27/2023Piper SandlerBoost Target$83.00 ➝ $88.00
7/25/2023Jefferies Financial GroupBoost TargetBuy$103.00 ➝ $107.00
7/19/2023Truist FinancialBoost Target$101.00 ➝ $105.00
7/18/2023Robert W. BairdInitiated CoverageOutperform$107.00
7/17/2023MizuhoBoost Target$95.00 ➝ $102.00
7/14/2023Morgan StanleyReiterated RatingOverweight ➝ Overweight$102.00
7/10/2023CitigroupBoost Target$101.00 ➝ $110.00
6/27/202358.comReiterated RatingReiterates
5/30/2023Morgan StanleyInitiated CoverageOverweight$102.00
5/18/2023Truist FinancialBoost Target$97.00 ➝ $101.00
4/28/2023BarclaysBoost Target$94.00 ➝ $102.00
4/27/2023Wells Fargo & CompanyBoost Target$78.00 ➝ $90.00
4/27/2023Piper SandlerBoost Target$80.00 ➝ $83.00
4/27/2023Truist FinancialBoost Target$93.00 ➝ $97.00
4/25/2023MizuhoBoost Target$85.00 ➝ $95.00
4/24/2023Stifel NicolausBoost Target$75.00 ➝ $87.00
4/17/2023Truist FinancialBoost TargetBuy$86.00 ➝ $93.00
4/3/2023CitigroupBoost TargetBuy$92.00 ➝ $97.00
3/28/2023UBS GroupInitiated CoverageNeutral$84.00
3/8/2023Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$97.00 ➝ $78.00
2/6/2023Raymond JamesDowngradeOutperform ➝ Market Perform
2/1/2023Canaccord Genuity GroupBoost TargetHold$68.00 ➝ $76.00
2/1/2023Truist FinancialBoost TargetBuy$85.00 ➝ $86.00
1/31/2023Sanford C. BernsteinDowngradeOutperform ➝ Underperform$95.00 ➝ $66.00
1/30/2023Piper SandlerDowngradeOverweight ➝ Neutral$95.00 ➝ $80.00
1/6/2023Morgan StanleyBoost TargetOverweight$92.00 ➝ $95.00
12/13/2022Raymond JamesLower TargetOutperform$85.00 ➝ $83.00
12/12/2022Canaccord Genuity GroupLower TargetHold ➝ Hold$78.00 ➝ $73.00
12/12/2022CitigroupLower TargetBuy$99.00 ➝ $92.00
12/9/2022Morgan StanleyLower Target$98.00 ➝ $92.00
12/7/2022MizuhoLower TargetBuy$100.00 ➝ $85.00
12/5/2022Stifel NicolausDowngradeBuy ➝ Hold$95.00 ➝ $75.00
12/1/2022Wolfe ResearchDowngradeOutperform ➝ Market Perform
11/28/2022Royal Bank of CanadaLower TargetOutperform$118.00 ➝ $105.00
11/3/2022The Goldman Sachs GroupLower TargetNeutral$97.00 ➝ $73.00
10/31/2022Raymond JamesLower TargetOutperform$120.00 ➝ $85.00
10/28/2022Royal Bank of CanadaLower TargetOutperform$128.00 ➝ $118.00
10/28/2022Morgan StanleyLower TargetOverweight$108.00 ➝ $98.00
10/28/2022Wells Fargo & CompanyLower TargetOverweight$121.00 ➝ $93.00
10/28/2022Truist FinancialLower TargetBuy$112.00 ➝ $95.00
10/28/2022CowenLower Target$125.00 ➝ $100.00
10/28/2022CowenLower Target$125.00 ➝ $100.00
10/28/2022Deutsche Bank AktiengesellschaftLower Target$113.00 ➝ $83.00
10/28/2022CitigroupLower TargetBuy$107.00 ➝ $99.00
10/28/2022OppenheimerDowngradeOutperform ➝ Market Perform
10/28/2022Piper SandlerLower TargetOverweight$120.00 ➝ $95.00
10/26/2022MizuhoInitiated CoverageBuy$100.00
10/17/2022BarclaysInitiated CoverageOverweight$96.00
10/14/2022Canaccord Genuity GroupLower Target$106.00 ➝ $91.00
10/12/2022Jefferies Financial GroupInitiated CoverageBuy$110.00
10/11/2022Morgan StanleyLower TargetOverweight$119.00 ➝ $108.00
10/5/2022CitigroupLower Target$118.00 ➝ $107.00
9/22/2022Truist FinancialLower TargetBuy$117.00 ➝ $112.00
7/29/2022Canaccord Genuity GroupDowngradeBuy ➝ Hold$115.00 ➝ $106.00
7/20/2022Truist FinancialLower TargetBuy$140.00 ➝ $120.00
7/18/2022Stifel NicolausLower Target$128.00 ➝ $115.00
7/15/2022Morgan StanleyLower TargetOverweight$136.00 ➝ $119.00
7/11/2022CowenLower Target$140.00 ➝ $125.00
7/11/2022CowenLower Target$140.00 ➝ $125.00
5/17/2022CitigroupLower TargetBuy$134.00 ➝ $115.00
4/27/2022Canaccord Genuity GroupLower Target$152.00 ➝ $137.00
4/27/2022CitigroupLower Target$138.00 ➝ $134.00
4/26/2022William BlairReiterated RatingOutperform
4/12/2022Truist FinancialInitiated CoverageBuy$145.00
4/5/2022Wolfe ResearchInitiated CoverageOutperform$134.00
3/16/2022Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$132.00 ➝ $135.00
3/1/2022Bank of AmericaInitiated CoverageNeutral ➝ Neutral
2/2/2022UBS GroupUpgradeNeutral ➝ Buy$121.00 ➝ $126.00
1/27/2022Evercore ISILower TargetOutperform$130.00 ➝ $122.00
1/27/2022UBS GroupLower TargetNeutral$125.00 ➝ $121.00
1/27/2022CitigroupLower TargetBuy$142.00 ➝ $138.00
1/27/2022Stifel NicolausLower TargetBuy$132.00 ➝ $120.00
1/27/2022Morgan StanleyLower TargetOverweight$148.00 ➝ $136.00
1/27/2022Raymond JamesLower TargetOutperform$134.00 ➝ $126.00
1/27/2022Piper SandlerLower Target$133.00 ➝ $125.00
1/21/2022Leerink PartnersLower TargetOutperform$135.00 ➝ $132.00
1/7/2022Credit Suisse GroupBoost TargetOutperform$131.00 ➝ $144.00
1/7/2022Morgan StanleyBoost TargetOverweight$144.00 ➝ $148.00
12/17/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$114.00 ➝ $140.00
12/15/2021CitigroupUpgradeNeutral ➝ Buy$120.00 ➝ $142.00
12/10/2021Raymond JamesBoost TargetOutperform ➝ Outperform$127.00 ➝ $134.00
12/9/2021Royal Bank of CanadaInitiated CoverageOutperform$142.00
12/9/2021Morgan StanleyBoost TargetOverweight$135.00 ➝ $144.00
12/9/2021Leerink PartnersBoost TargetOutperform$130.00 ➝ $135.00
12/8/2021Piper SandlerBoost TargetOverweight ➝ Overweight$123.00 ➝ $133.00
12/6/2021Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$126.00
10/29/2021Jefferies Financial GroupBoost TargetBuy$130.00 ➝ $135.00
10/28/2021Credit Suisse GroupBoost TargetOutperform$126.00 ➝ $130.00
10/28/2021Wells Fargo & CompanyBoost TargetEqual Weight$115.00 ➝ $126.00
10/28/2021Raymond JamesBoost TargetOutperform$122.00 ➝ $127.00
10/28/2021CitigroupBoost TargetNeutral$113.00 ➝ $120.00
8/3/2021The Goldman Sachs GroupBoost TargetNeutral$93.00 ➝ $105.00
8/2/2021Raymond JamesBoost TargetOutperform$101.00 ➝ $122.00
7/30/2021Credit Suisse GroupBoost TargetOutperform$112.00 ➝ $126.00
7/30/2021Morgan StanleyBoost TargetOverweight$108.00 ➝ $135.00
7/30/2021OppenheimerBoost TargetOutperform$97.00 ➝ $120.00
7/30/2021Stifel NicolausBoost TargetBuy$103.00 ➝ $120.00
7/30/2021UBS GroupBoost TargetNeutral$98.00 ➝ $115.00
7/30/2021Leerink PartnersBoost TargetOutperform$125.00 ➝ $130.00
7/30/2021Jefferies Financial GroupBoost TargetBuy$110.00 ➝ $130.00
7/30/2021Wells Fargo & CompanyBoost TargetEqual Weight$93.00 ➝ $115.00
7/30/2021Deutsche Bank AktiengesellschaftBoost TargetHold$84.00 ➝ $113.00
7/27/2021Piper SandlerBoost TargetOverweight$105.00 ➝ $120.00
7/23/2021CowenBoost TargetOutperform$100.00 ➝ $125.00
7/20/2021Leerink PartnersBoost TargetOutperform$106.00 ➝ $125.00
5/24/2021BarclaysInitiated CoverageOverweight$110.00
4/21/2021Morgan StanleyBoost TargetOverweight$99.00 ➝ $108.00
4/21/2021Raymond JamesBoost TargetOutperform$96.00 ➝ $101.00
4/21/2021Wells Fargo & CompanyBoost TargetEqual Weight$87.00 ➝ $93.00
4/21/2021Piper SandlerBoost TargetOverweight$97.00 ➝ $105.00
4/15/2021Atlantic SecuritiesInitiated CoverageNeutral$85.00
4/5/2021Evercore ISIUpgradeIn-Line ➝ Outperform
12/16/2020Smith Barney CitigroupDowngradeBuy ➝ Neutral
12/14/2020Morgan StanleyBoost TargetOverweight$88.00 ➝ $99.00
12/11/2020Raymond JamesBoost TargetOutperform$90.00 ➝ $96.00
12/11/2020Piper SandlerBoost TargetOverweight$93.00 ➝ $98.00
12/11/2020Leerink PartnersBoost TargetOutperform$100.00 ➝ $106.00
12/7/2020Credit Suisse GroupBoost Target$97.00 ➝ $111.00
11/18/2020Wells Fargo & CompanyBoost TargetEqual Weight$84.00 ➝ $87.00
10/27/2020Jefferies Financial GroupBoost TargetBuy$95.00 ➝ $105.00
10/22/2020Credit Suisse GroupBoost TargetOutperform$92.00 ➝ $97.00
10/22/2020Raymond JamesBoost TargetOutperform$88.00 ➝ $90.00
10/19/2020CowenBoost TargetOutperform$85.00 ➝ $100.00
10/14/2020Piper SandlerBoost TargetOverweight$91.00 ➝ $93.00
10/12/2020Leerink PartnersBoost TargetOutperform$95.00 ➝ $100.00
9/11/2020Wolfe ResearchInitiated CoverageUnderperform
7/24/2020Stifel NicolausBoost TargetBuy$85.00 ➝ $90.00
7/24/2020Jefferies Financial GroupBoost TargetBuy$87.00 ➝ $95.00
7/24/2020Credit Suisse GroupBoost TargetOutperform$88.00 ➝ $92.00
7/24/2020Morgan StanleyBoost TargetOverweight$83.00 ➝ $88.00
7/24/2020Leerink PartnersBoost TargetOutperform$90.00 ➝ $95.00
7/24/2020Raymond JamesBoost TargetOutperform$83.00 ➝ $88.00
7/24/2020Piper SandlerBoost TargetPositive ➝ Overweight$88.00 ➝ $91.00
7/13/2020OppenheimerInitiated CoverageBuy$93.00
6/29/2020Morgan StanleyLower TargetOverweight$83.33 ➝ $83.00
6/2/2020Credit Suisse GroupLower TargetOutperform$88.00
6/1/2020Morgan StanleyLower TargetOverweight$83.33 ➝ $83.00
4/28/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$83.33 ➝ $76.67
4/27/2020BarclaysReiterated RatingUnderweight$55.00 ➝ $51.67
4/24/2020CfraBoost TargetBuy$67.00 ➝ $77.00
4/24/2020Raymond JamesBoost TargetOutperform$76.67 ➝ $83.33
4/24/2020Stifel NicolausBoost TargetBuy$76.67 ➝ $85.00
4/24/2020Piper SandlerLower TargetOverweight$90.00 ➝ $88.33
4/24/2020Morgan StanleyBoost TargetOverweight$80.33 ➝ $83.33
4/24/2020Credit Suisse GroupBoost TargetOutperform$86.67 ➝ $87.33
4/24/2020Wells Fargo & CompanyBoost TargetOverweight$71.67 ➝ $83.33
4/24/2020CitigroupBoost TargetBuy$80.00 ➝ $85.00
4/23/2020BTIG ResearchReiterated RatingHold
4/22/2020Deutsche Bank AktiengesellschaftLower TargetHold$81.67 ➝ $75.00
4/20/2020CowenLower TargetTop Pick ➝ Outperform$91.67 ➝ $83.33
4/19/2020Leerink PartnersDowngradeOutperform ➝ Market Perform
4/17/2020Leerink PartnersUpgradeMarket Perform ➝ Outperform$90.00
4/9/2020Raymond JamesLower TargetOutperform$87.67 ➝ $76.67
4/6/2020Wells Fargo & CompanyLower TargetOverweight$90.67 ➝ $71.67
3/27/2020Morgan StanleyLower TargetOverweight$90.00 ➝ $80.33
3/27/2020CitigroupLower TargetBuy$84.00 ➝ $80.00
3/13/2020CfraUpgradeSell ➝ Hold$69.00 ➝ $67.00
3/6/2020Credit Suisse GroupLower TargetOutperform$92.67 ➝ $89.00
3/4/2020CitigroupInitiated CoverageBuy$84.00
2/12/2020The Goldman Sachs GroupInitiated CoverageNeutral$84.33
2/6/2020BTIG ResearchInitiated CoverageHold
1/31/2020CfraBoost TargetSell$68.33 ➝ $69.00
1/31/2020Stifel NicolausBoost TargetBuy$91.67 ➝ $93.33
1/31/2020Wells Fargo & CompanyBoost TargetOverweight$90.00 ➝ $90.67
1/31/2020Deutsche Bank AktiengesellschaftBoost TargetHold$78.67 ➝ $81.67
1/31/2020Credit Suisse GroupBoost TargetOutperform$91.67 ➝ $92.67
1/31/2020Piper SandlerBoost TargetOverweight$87.33 ➝ $90.00
1/31/2020UBS GroupBoost TargetNeutral$85.00 ➝ $86.67
1/9/2020OppenheimerUpgradeMarket Perform ➝ Buy$93.33
1/3/2020Deutsche Bank AktiengesellschaftInitiated CoverageHold$54.67
12/17/2019CowenReiterated RatingBuy$91.67
12/9/2019Piper Sandler CompaniesBoost TargetOverweight$85.00 ➝ $87.33
12/6/2019UBS GroupBoost TargetNeutral$83.33 ➝ $85.00
12/6/2019Wells Fargo & CompanyBoost TargetOutperform$87.33 ➝ $90.00
12/6/2019Credit Suisse GroupBoost TargetOutperform$89.67 ➝ $91.67
12/6/2019Morgan StanleyBoost TargetOverweight$82.67 ➝ $90.00
12/6/2019Raymond JamesBoost TargetOutperform$85.00 ➝ $87.67
12/3/2019Jefferies Financial GroupBoost TargetBuy$85.00 ➝ $95.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.47 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 36 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024
  • 44 very positive mentions
  • 29 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
5/25/2024
  • 27 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 23 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 31 very positive mentions
  • 30 positive mentions
  • 7 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 34 very positive mentions
  • 14 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
Mentions as of
9/22/2024
  • 29 very positive mentions
  • 52 positive mentions
  • 7 negative mentions
  • 2 very negative mentions
Mentions as of
10/22/2024
  • 66 very positive mentions
  • 154 positive mentions
  • 7 negative mentions
  • 4 very negative mentions
Mentions as of
11/21/2024

Current Sentiment

  • 66 very positive mentions
  • 154 positive mentions
  • 7 negative mentions
  • 4 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Edwards Lifesciences logo
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Read More

Today's Range

Now: $69.54
Low: $68.45
High: $70.61

50 Day Range

MA: $67.61
Low: $64.54
High: $70.63

52 Week Range

Now: $69.54
Low: $58.93
High: $96.12

Volume

3,473,626 shs

Average Volume

4,653,856 shs

Market Capitalization

$41.01 billion

P/E Ratio

10.03

Dividend Yield

N/A

Beta

1.12

Frequently Asked Questions

What sell-side analysts currently cover shares of Edwards Lifesciences?

The following equities research analysts have issued reports on Edwards Lifesciences in the last twelve months: Baird R W, Bank of America Co., Barclays PLC, Canaccord Genuity Group Inc., Citigroup Inc., Daiwa America, Daiwa Capital Markets, Deutsche Bank Aktiengesellschaft, Evercore ISI, Jefferies Financial Group Inc., JPMorgan Chase & Co., Mizuho, Morgan Stanley, Oppenheimer Holdings Inc., OTR Global, Piper Sandler, Robert W. Baird, Royal Bank of Canada, Sanford C. Bernstein, Stifel Nicolaus, StockNews.com, TD Cowen, The Goldman Sachs Group, Inc., Truist Financial Co., UBS Group AG, Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for EW.

What is the current price target for Edwards Lifesciences?

0 Wall Street analysts have set twelve-month price targets for Edwards Lifesciences in the last year. Their average twelve-month price target is $75.67, suggesting a possible upside of 8.8%. Mizuho has the highest price target set, predicting EW will reach $105.00 in the next twelve months. Wolfe Research has the lowest price target set, forecasting a price of $57.00 for Edwards Lifesciences in the next year.
View the latest price targets for EW.

What is the current consensus analyst rating for Edwards Lifesciences?

Edwards Lifesciences currently has 16 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in EW, but not buy more shares or sell existing shares.
View the latest ratings for EW.

What other companies compete with Edwards Lifesciences?

Other companies that are similar to Edwards Lifesciences include Stryker, Boston Scientific, Medtronic, Becton, Dickinson and Company and ResMed. Learn More about companies similar to Edwards Lifesciences.

How do I contact Edwards Lifesciences' investor relations team?

Edwards Lifesciences' physical mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company's listed phone number is (949) 250-2500 and its investor relations email address is [email protected]. The official website for Edwards Lifesciences is www.edwards.com. Learn More about contacing Edwards Lifesciences investor relations.